Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at Upcoming Conferences in April

TEL AVIV, Israel, March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American...
March 19, 2019 07:00 ET | Source: VBL Therapeutics

VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment

TEL AVIV, Israel, March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy...
March 14, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28

TEL AVIV, Israel, March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
March 11, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer on March 18

TEL AVIV, Israel, March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
February 26, 2019 08:00 ET | Source: VBL Therapeutics

VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA)

TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting...
February 20, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority

TEL AVIV, Israel, Feb. 20, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (the “Company”) today announced that it has been awarded a non-dilutive grant of over 10 million New Israeli...
February 19, 2019 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26

TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announces that the Company will present new data on the potential of its VB-600 platform targeting MOSPD2...
November 21, 2018 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28

TEL AVIV, Israel, Nov. 21, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
November 20, 2018 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Third Quarter 2018 Financial Results

TEL AVIV, Israel, Nov. 20, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, 2018 and provided a corporate update. ...
November 16, 2018 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting

Additional Analyses Provide Insight into Treatment Effect of VB-111 TEL AVIV, Israel, Nov. 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), is reporting results today from its Phase 3...